Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1464289

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government who is responsible for leading the COVID-19 enhanced protection programme (EPP); and what is the process for (1) charities, and (2) patient organisations, to be designated as stakeholders for the programme.
	tabling member printed	Lord Mendelsohn
	uin	HL349
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL348 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1661526

	registered interest
	date	18/09/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Screening and Surveillance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the UK Health Security Agency’s observation that “in the UK, the current surveillance systems do not support an assessment of comparative severity between variants”, published on 14 September; and what plans they have to increase PCR testing and COVID-19 surveillance in England.
	tabling member printed	Lord Mendelsohn
	uin	HL10263
	answer	answer is ministerial correction date of answer 02/10/2023 answer text <p>Trends in disease severity and outcomes can be monitored over time through hospital data. The UK Health Security Agency (UKHSA) receives vital data from those who are admitted to hospital with symptoms, and UKHSA is using genome sequencing to detect and assess severity and vaccine effectiveness against new variants.</p><p>While reduced polymerase chain reaction (PCR) testing in the community limits comparisons of variant severity, surveillance metrics based on current testing continue to provide useful indicators of recent trends.</p><p>UKHSA retains laboratory capacity and an ability to scale PCR and lateral flow device testing back up should it be needed.</p><p>Planning for the restart of community surveillance for the winter season, when health pressures usually rise, is in progress. A national surveillance report is published every two weeks, and this will increase to once every week in the winter season.</p> answering member printed Lord Markham question first answered 02/10/2023 12:39:28 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1624546

	registered interest
	date	27/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what provision is being made for immunocompromised people who are struggling financially from the financial impact of the COVID-19 pandemic and its ongoing challenges for those still vulnerable to the virus; and how they will support those affected in the light of their prescription waiver on anti-viral drugs being withdrawn
	tabling member printed	Lord Mendelsohn
	uin	HL7529
	answer	answer is ministerial correction date of answer 05/05/2023 answer text <p>Treatments for COVID-19 are available free of charge on the National Health Service in England for eligible high-risk patients with a positive COVID-19 test result. In addition, the charge waiver will continue to apply to therapeutic treatments made available through the HEAL-COVID and STIMULATE-ICP trials.</p><p>There are also a wide range of exemptions from prescription charges already in place, covering children, pregnant women, those over 60 years old, people on certain income related benefits or whose partner is in receipt of those benefits as well as those with specific medical conditions. Around 89% of prescription items are free on the NHS in England. On top of that, people on a low income can apply for support through the NHS Low Income Scheme, and all patients can also buy a pre-payment certificate which covers all the items they need for just over £2 per week.</p> answering member printed Lord Markham question first answered 05/05/2023 11:45:51 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1523500

	registered interest
	date	18/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what data they have, if any, to show the proportion of people who tested positive for COVID-19 and were eligible for treatments through the Covid Medicines Delivery Unit (CMDU) and who were able to access such treatments.
	tabling member printed	Lord Mendelsohn
	uin	HL2693
	answer	answer is ministerial correction date of answer 28/10/2022 answer text <p>To date, over 75,000 patients have received treatments to date via COVID Medicine Delivery Units (CMDUs). On average, between 20 to 25% of individuals in England who test positive for COVID-19 and are digitally identified as potentially eligible for treatments in community settings subsequently receive one of four treatment options available via a CMDU.</p><p> </p><p>Where potentially eligible patients do not progress to treatments, this may be because they are not experiencing symptoms, are already recovering or are not in one of the eligible highest risk groups following clinical assessment. Some individuals also choose to decline treatment, whilst others cannot be contacted via the details provided at the point of registering their test result.</p><p> </p><p>Since the service’s inception, new treatment options have been introduced based on available evidence, faster access has been achieved via lateral flow device tests and we are now able to digitally identify more potentially eligible patients. We also receive regular feedback from patients, patient groups and charities and from the care home sector to understand and improve the patient experience and with general practitioners and hospital specialists, we are raising awareness of eligibility, access and treatment options.</p> answering member printed Lord Markham grouped question UIN HL2694 question first answered 28/10/2022 14:04:26 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1523501

	registered interest
	date	18/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the report by OpenSAFELY on behalf of NHS England published on 13 October which showed that 24 per cent of potentially eligible patients received treatments through the Covid Medicines Delivery Unit (CMDU), what additional criteria are being used by CDMUs to improve access to COVID-19 treatments.
	tabling member printed	Lord Mendelsohn
	uin	HL2694
	answer	answer is ministerial correction date of answer 28/10/2022 answer text <p>To date, over 75,000 patients have received treatments to date via COVID Medicine Delivery Units (CMDUs). On average, between 20 to 25% of individuals in England who test positive for COVID-19 and are digitally identified as potentially eligible for treatments in community settings subsequently receive one of four treatment options available via a CMDU.</p><p> </p><p>Where potentially eligible patients do not progress to treatments, this may be because they are not experiencing symptoms, are already recovering or are not in one of the eligible highest risk groups following clinical assessment. Some individuals also choose to decline treatment, whilst others cannot be contacted via the details provided at the point of registering their test result.</p><p> </p><p>Since the service’s inception, new treatment options have been introduced based on available evidence, faster access has been achieved via lateral flow device tests and we are now able to digitally identify more potentially eligible patients. We also receive regular feedback from patients, patient groups and charities and from the care home sector to understand and improve the patient experience and with general practitioners and hospital specialists, we are raising awareness of eligibility, access and treatment options.</p> answering member printed Lord Markham grouped question UIN HL2693 question first answered 28/10/2022 14:04:26 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1624578

	registered interest
	date	27/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact on immunocompromised people arising from (1) shutting down the Anti-Viral task force, (2) ending any stakeholder engagement through the Enhanced Protection Programme, (3) withdrawing vaccine boosters for the families of the immunocompromised, (4) ending the collection of data on Covid infections via the Office for National Statistics, and (5) ending access to anti-virals through the Covid Medicines Delivery Units and transferring this to GPs; and what steps they are taking to enhance the protection of the clinically vulnerable community from COVID-19.
	tabling member printed	Lord Mendelsohn
	uin	HL7531
	answer	answer is ministerial correction date of answer 16/05/2023 answer text <p>Those that remain at higher risk from COVID-19 remain a priority for the Government and continue to be offered enhanced protections such as treatments, booster vaccines, free lateral flow tests and public health advice.</p><p>Functions of the Antivirals and Therapeutics Taskforce (ATTF) have now moved to different parts of the Department and the National Health Service. The NHS will continue to deliver treatment for COVID-19 patients and will operate in line with evidence-based recommendations from National Institute for Health and Care Excellence, following the established processes in this area.</p><p>Following the closure of the enhanced protection programme stakeholder forum, UK Health Security Agency (UKHSA) recognises the importance of continuing to engage with patient charities and other stakeholders, and further information on continuing stakeholder engagement will be shared in due course.</p><p>On 27 January 2023 the Government accepted Joint Committee on Vaccination and Immunisation (JCVI) interim advice that there could be a further booster programme in autumn 2023 for those at higher risk of severe COVID-19 in preparation for winter 2023 to 2024. JCVI will continue its rolling review of the vaccination programme and will provide further advice on which groups including carers and family members of immunosuppressed individuals should be included in the autumn 2023 COVID-19 vaccination programme in due course.</p><p>The approach to COVID-19 surveillance is being actively reviewed to ensure it is proportionate, cost effective and considered alongside how we monitor a range of other infectious diseases that present a similar threat.</p><p>The UKHSA will continue to publish regular reports on COVID-19 which will contribute to our situational awareness. These include our weekly surveillance reports, which provide data on infection rates and hospitalisation numbers. We also maintain the ability to track the latest variants through our genomics capabilities which assess the risks posed by different strains of the virus.</p><p>Integrated care boards (ICBs) are responsible for the continued delivery of COVID-19 treatments, including where appropriate transitioning the delivery of community-based COVID-19 treatments away from covid medicines delivery unit to routine care pathways by the end of June. ICBs have the flexibility to create a routine patient access pathway that best meets local needs and circumstances, including for immunocompromised patients.</p><p>NHS England is working closely with local health systems, supporting ICBs to develop service delivery plans which ensure continued timely access to assessment and treatment that meet the needs of their local populations. To support the transition away from pandemic-specific arrangements NHS England is regularly engaging with charities, patient groups and other stakeholders to understand where national and local action may be required to ensure transition readiness.</p><p>NHS England is providing national communications to patients, healthcare professionals and local system leaders to ensure clarity on upcoming changes.</p><p>Highest risk patients will continue to have access to free tests, however the way patients will access tests may change later this year.</p><p> </p> answering member printed Lord Markham question first answered 16/05/2023 15:33:26 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1549709

	registered interest
	date	07/12/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what percentage of people who received COVID-19 treatment in a community setting subsequently died from COVID-19.
	tabling member printed	Lord Mendelsohn
	uin	HL4105
	answer	answer is ministerial correction date of answer 15/12/2022 answer text <p>This information is not held centrally in the format requested. NHS England continues to work with research organisations to understand the impact of treatments on clinical outcomes, such as the RECOVERY, PANORAMIC, OpenSAFELY or ISARIC studies.</p> answering member printed Lord Markham question first answered 15/12/2022 12:10:03 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1467956

	registered interest
	date	06/06/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what budget they have set for the purchase of new Antiviral or Monoclonal Antibody drug treatments for COVID-19, including (1) those under current review like Evusheld, and (2) those under future review by the COVID-19 Antivirals and Therapeutics Taskforce; and if these should prove efficacious in the protection of immunosuppressed patients, whether this funding will be sufficient to meet current supply needs.
	tabling member printed	Lord Mendelsohn
	uin	HL651
	answer	answer is ministerial correction date of answer 20/06/2022 answer text <p>There is currently no funding allocated for these treatments. Funding for additional procurement of novel treatments is considered on a case-by-case basis, as guided by clinical need and subject to business cases and due process.</p> answering member printed Lord Kamall question first answered 20/06/2022 15:31:10 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1539335

	registered interest
	date	03/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, whether they will (1) consult a wider group with more diverse viewpoints and expertise to make a recommendation on the efficacy of Evusheld, and (2) engage other committees with expertise like SAGE and the JCVI on this treatment.
	tabling member printed	Lord Mendelsohn
	uin	HL3197
	answer	answer is ministerial correction date of answer 10/11/2022 answer text <p>There are no plans to consult with the Joint Committee on Vaccination and Immunisation or the Scientific Advisory Group on Emergencies as these bodies do not have a remit on decisions on new treatments. RAPID C-19 consists of scientific experts, including clinicians, pharmacists, evidence assessors and researchers, who provide independent clinical advice to the Chief Medical Officer for England. RAPID C-19’s expertise is related to the organisations represented, which include the main healthcare agencies involved in decisions on research, regulation, and introducing new treatments into the National Health Service.</p><p> </p><p>NHS England created a national expert working group (EWG) to support development of a national clinical policy, with a focus on clinical effectiveness and eligibility criteria. The EWG is chaired by a senior NHS representative and the membership includes national experts, frontline clinicians and involves officials from the devolved administrations. The EWG has also considered emerging prophylactic agents and its members have specific expertise in immunology and virology. RAPID C-19 was also advised by the independent COVID-19 Prophylaxis Oversight Group, which is chaired by an expert on infectious diseases and clinical trials.</p> answering member printed Lord Markham grouped question UIN HL3198 question first answered 10/11/2022 16:47:53 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1539336

	registered interest
	date	03/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, why (1) SAGE, and (2) the JCVI, were not consulted on the decision on whether to purchase Evusheld.
	tabling member printed	Lord Mendelsohn
	uin	HL3198
	answer	answer is ministerial correction date of answer 10/11/2022 answer text <p>There are no plans to consult with the Joint Committee on Vaccination and Immunisation or the Scientific Advisory Group on Emergencies as these bodies do not have a remit on decisions on new treatments. RAPID C-19 consists of scientific experts, including clinicians, pharmacists, evidence assessors and researchers, who provide independent clinical advice to the Chief Medical Officer for England. RAPID C-19’s expertise is related to the organisations represented, which include the main healthcare agencies involved in decisions on research, regulation, and introducing new treatments into the National Health Service.</p><p> </p><p>NHS England created a national expert working group (EWG) to support development of a national clinical policy, with a focus on clinical effectiveness and eligibility criteria. The EWG is chaired by a senior NHS representative and the membership includes national experts, frontline clinicians and involves officials from the devolved administrations. The EWG has also considered emerging prophylactic agents and its members have specific expertise in immunology and virology. RAPID C-19 was also advised by the independent COVID-19 Prophylaxis Oversight Group, which is chaired by an expert on infectious diseases and clinical trials.</p> answering member printed Lord Markham grouped question UIN HL3197 question first answered 10/11/2022 16:47:53 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn